DexCom Stock (NASDAQ:DXCM), Trade Ideas

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

News

Short Ideas

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

DXCM

The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades.

Micron, Dropbox And 2 Other Stocks Insiders Are Selling

Analyst Color

Initiation

Analyst Ratings

DexCom Inc’s (NASDAQ: DXCM) Stelo Glucose Biosensor System has been approved by the Food and Drug Administration (FDA) as the first over-the-counter (OTC)

DexCom Is &#39;Expanding Rapidly&#39; With Multi-Year Runway Ahead, Bullish Analyst Says

Long Ideas

Media

PLTR

On CNBC’s &#34;Halftime Report Final Trades,&#34;  Jenny Harrington of Gilman Hill Asset Management named  SL Green Realty Corp.

Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC&#39;s &#39;Final Trades&#39;

DexCom Inc

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 5 years by 23.93% on an annualized basis producing an average annual return of 35.38%. Currently, DexCom has a market capitalization of $51.74 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 5 years ago, it would be worth $4,603.38 today based on a price of $134.20 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713380445_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today

Deep-pocketed investors have adopted a bullish approach towards DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DXCM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for DexCom. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 5 are puts, totaling $243,316, and 5 are calls, amounting to $151,590.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $175.0 for DexCom over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DexCom's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale trades within a strike price range from $120.0 to $175.0 in the last 30 days. 
<h3>DexCom 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712867556_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.4</td>
<td>$125.00</td>
<td>$63.6K</td>
<td style="text-align: right;">23</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$7.3</td>
<td>$7.1</td>
<td>$7.3</td>
<td>$120.00</td>
<td>$58.4K</td>
<td style="text-align: right;">56</td>
<td style="text-align: right;">235</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.5</td>
<td>$17.2</td>
<td>$17.5</td>
<td>$140.00</td>
<td>$52.5K</td>
<td style="text-align: right;">135</td>
<td style="text-align: right;">109</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$120.00</td>
<td>$42.6K</td>
<td style="text-align: right;">186</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.8</td>
<td>$9.6</td>
<td>$9.8</td>
<td>$175.00</td>
<td>$34.3K</td>
<td style="text-align: right;">517</td>
<td style="text-align: right;">37</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Where Is DexCom Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,057,557, with DXCM's price down by -0.5%, positioned at $139.62.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About DexCom</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $162.0.
<ul>
<li>Maintaining their stance, an analyst from UBS continues to hold a Buy rating for DexCom, targeting a price of $163. </li>
<li>Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on DexCom with a target price of $161. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for DexCom, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On DexCom

4 analysts have shared their evaluations of DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for DexCom, revealing an average target of $160.0, a high estimate of $165.00, and a low estimate of $151.00. This upward trend is evident, with the current average reflecting a 7.15% increase from the previous average price target of $149.33.
<img src="https://www.benzinga.com/files/images/story/2024/1712772070_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of DexCom by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$163.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$161.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$151.00</td>
<td>$147.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DexCom's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Discovering DexCom: A Closer Look</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Unraveling the Financial Story of DexCom</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: DexCom's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 26.9%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.78%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): DexCom's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): DexCom's ROA excels beyond industry benchmarks, reaching 3.99%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.25, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: DexCom In The Eyes Of 4 Experts

UBS analyst Danielle Antalffy maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $153 to $163.

Price Target

UBS Maintains Buy on DexCom, Raises Price Target to $163

Rumors

Watching DexCom; Hearing Investor Business Daily's Swingtrader Names Stock As Buy

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $148 to $161.

Citigroup Maintains Buy on DexCom, Raises Price Target to $161

The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company&rsquo;s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Micron Technology </h3>
<ul>
<li>The Trade: Micron Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mu#NASDAQ">MU</a>) EVP, Chief People Officer April S Arnzen <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 4,890 shares </a> at an average price of $119.30. The insider received around $583,377 from selling those shares.</li>
<li>What&rsquo;s Happening: Micron reported better-than-expected second-quarter financial results and issued strong third-quarter guidance on March 20, 2024.</li>
<li>What Micron Technology Does: Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips.</li>
</ul>
Have a look at our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>DexCom</h3>
<ul>
<li>The Trade: DexCom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxcm#NASDAQ">DXCM</a>) EVP Chief Legal Officer Michael Jon Brown <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 2,624 shares </a> at an average price of $140.04. The insider received around $367,472 from selling those shares.</li>
<li>What&rsquo;s Happening: On March 13, RBC Capital initiated coverage on the stock with an Outperform rating and $165 price target.</li>
<li>What DexCom Does: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients.</li>
</ul>
<h3>Williams-Sonoma </h3>
<ul>
<li>The Trade: Williams-Sonoma, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wsm#NYSE">WSM</a>) CEO POTTERY BARN BRANDS Marta Benson <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 2,184 shares </a> at an average price of $313.98. The insider received around $685,721 from selling those shares.</li>
<li>What&rsquo;s Happening: On March 26, Evercore ISI Group analyst Oliver Wintermantel maintained Williams-Sonoma with an In-Line and raised the price target from $300 to $320.</li>
<li>What Williams-Sonoma Does: With a retail and direct-to-consumer presence, Williams-Sonoma is a player in the $300 billion domestic home category and $450 billion international home market, focused on expanding its exposure in the B2B ($80 billion total addressable market), marketplace, and franchise areas.</li>
</ul>
<h3>Dropbox </h3>
<ul>
<li>The Trade: Dropbox, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dbx#NASDAQ">DBX</a>) CFO Timothy Regan <a href="https://www.benzinga.com/sec/insider-trades/"> sold a total of 3,000 shares </a> at an average price of $24.36. The insider received around $73,074 from selling those shares.</li>
<li>What&rsquo;s Happening: On March 22, Citigroup analyst Steven Enders maintained Dropbox with a Neutral and lowered the price target from $31 to $27.</li>
<li>What Dropbox Does: Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37975916/jim-cramer-likes-crown-castle-but-cant-recommend-archer-aviation-it-has-no-earnings-powe"> Jim Cramer Likes Crown Castle, But Can&#39;t Recommend Archer Aviation: It Has &#39;No Earnings Power&#39; </a>

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 25.38% on an annualized basis producing an average annual return of 38.72%. Currently, DexCom has a market capitalization of $51.42 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $139,310.17 today based on a price of $133.38 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711391419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today

Benzinga's options scanner has just identified more than 8 option transactions on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), with a cumulative value of $548,553. Concurrently, our algorithms picked up 5 puts, worth a total of 372,044.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $97.5 to $131.0 for DexCom over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DexCom's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale trades within a strike price range from $97.5 to $131.0 in the last 30 days. 
<h3>DexCom Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1710960349_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/22/24</td>
<td>$131.00</td>
<td>$252.8K</td>
<td style="text-align: right;">56</td>
<td>1.0K</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$123.00</td>
<td>$129.9K</td>
<td style="text-align: right;">0</td>
<td>14</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$125.00</td>
<td>$53.4K</td>
<td style="text-align: right;">175</td>
<td>14</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$130.00</td>
<td>$46.6K</td>
<td style="text-align: right;">269</td>
<td>20</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/22/24</td>
<td>$131.00</td>
<td>$34.3K</td>
<td style="text-align: right;">56</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
After a thorough review of the options trading surrounding DexCom, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is DexCom Standing Right Now?</h3>
<ul>
<li>With a trading volume of 962,351, the price of DXCM is up by 0.4%, reaching $134.7.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
<h3>What Analysts Are Saying About DexCom</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $165.0.
<ul>
<li>In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $165. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DexCom's Options: A Look at What the Big Money is Thinking

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$11.00</td>
<td>$25.5K</td>
<td>109</td>
<td style="text-align: right;">621</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$175.00</td>
<td>$101.5K</td>
<td>1.1K</td>
<td style="text-align: right;">512</td>
</tr>
<tr>
<td>SHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$15.00</td>
<td>$64.1K</td>
<td>27</td>
<td style="text-align: right;">285</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$180.00</td>
<td>$33.1K</td>
<td>3.4K</td>
<td style="text-align: right;">272</td>
</tr>
<tr>
<td>IMTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.00</td>
<td>$78.2K</td>
<td>4</td>
<td style="text-align: right;">202</td>
</tr>
<tr>
<td>LQDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$10.00</td>
<td>$38.2K</td>
<td>259</td>
<td style="text-align: right;">115</td>
</tr>
<tr>
<td>MDGL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$250.00</td>
<td>$27.7K</td>
<td>120</td>
<td style="text-align: right;">83</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$155.00</td>
<td>$45.8K</td>
<td>293</td>
<td style="text-align: right;">33</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$260.00</td>
<td>$32.7K</td>
<td>420</td>
<td style="text-align: right;">16</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$910.00</td>
<td>$44.1K</td>
<td>0</td>
<td style="text-align: right;">5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we observe a call option trade with bullish sentiment. It expires in 32 day(s) on April 19, 2024. Parties traded 300 contract(s) at a $11.00 strike. The total cost received by the writing party (or parties) was $25.5K, with a price of $85.0 per contract. There were 109 open contracts at this strike prior to today, and today 621 contract(s) were bought and sold. 
• Regarding ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we observe a put option sweep with bullish sentiment. It expires in 32 day(s) on April 19, 2024. Parties traded 169 contract(s) at a $175.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $101.5K, with a price of $600.0 per contract. There were 1100 open contracts at this strike prior to today, and today 512 contract(s) were bought and sold. 
• Regarding SHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>), we observe a call option sweep with bullish sentiment. It expires in 60 day(s) on May 17, 2024. Parties traded 715 contract(s) at a $15.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $64.1K, with a price of $95.0 per contract. There were 27 open contracts at this strike prior to today, and today 285 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 32 day(s) on April 19, 2024. This event was a transfer of 107 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $33.1K, with a price of $310.0 per contract. There were 3471 open contracts at this strike prior to today, and today 272 contract(s) were bought and sold. 
• For IMTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMTX#NASDAQ">IMTX</a>), we notice a call option trade that happens to be bearish, expiring in 305 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $78.2K, with a price of $391.0 per contract. There were 4 open contracts at this strike prior to today, and today 202 contract(s) were bought and sold. 
• For LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we notice a call option sweep that happens to be bearish, expiring in 123 day(s) on July 19, 2024. This event was a transfer of 58 contract(s) at a $10.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $38.2K, with a price of $660.0 per contract. There were 259 open contracts at this strike prior to today, and today 115 contract(s) were bought and sold. 
• Regarding MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we observe a put option trade with bearish sentiment. It expires in 32 day(s) on April 19, 2024. Parties traded 44 contract(s) at a $250.00 strike. The total cost received by the writing party (or parties) was $27.7K, with a price of $630.0 per contract. There were 120 open contracts at this strike prior to today, and today 83 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a call option trade that happens to be bearish, expiring in 305 day(s) on January 17, 2025. This event was a transfer of 33 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $45.8K, with a price of $1390.0 per contract. There were 293 open contracts at this strike prior to today, and today 33 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be bullish, expiring in 95 day(s) on June 21, 2024. This event was a transfer of 15 contract(s) at a $260.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.7K, with a price of $2185.0 per contract. There were 420 open contracts at this strike prior to today, and today 16 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option sweep with bearish sentiment. It expires in 95 day(s) on June 21, 2024. Parties traded 3 contract(s) at a $910.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $44.1K, with a price of $14705.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

AMGN

HROW

IMTX

LQDA

MDGL

10 Health Care Stocks Whale Activity In Today's Session

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 24.4% on an annualized basis producing an average annual return of 37.94%. Currently, DexCom has a market capitalization of $49.99 billion. 
Buying $1000 In DXCM: If an investor had bought $1000 of DXCM stock 15 years ago, it would be worth $120,465.12 today based on a price of $129.67 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1710448217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

General

DexCom shares are trading higher after RBC Capital initiated coverage on the stock with an Outperform rating and $165 price target.

DexCom Inc&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxcm#NASDAQ">DXCM</a>) Stelo Glucose Biosensor System has been approved by the Food and Drug Administration (FDA) as the first over-the-counter (OTC)<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37522301/fda-approval-for-dexcoms-stelo-opens-continuous-glucose-monitoring-to-masses-analys"> continuous glucose monitor (CGM)</a>.
DexCom&rsquo;s global total addressable market (TAM) is expanding rapidly, positioning the company for revenue upside, according to RBC Capital Markets.
The DexCom Analyst: Shagun Singh initiated coverage of DexCom with an Outperform rating and price target of $165.
The DexCom Thesis: The San Diego-based company has &ldquo;a multi-year runway ahead&rdquo; and appears poised to become one of the fastest-growing large-cap MedTech companies, Singh said in the initiation note.
Check out<a href="https://www.benzinga.com/analyst-stock-ratings"> other analyst stock ratings</a>.
Stelo, which is scheduled for a launch in summer 2024, is an immediate and major growth catalyst for DexCom, the analyst stated.
The company has received the first FDA-clearance for a non-prescription CGM, which &ldquo;opens up 25MM patient Type 2 non-II market for patients TAM on oral, injectable, diet, and exercise&rdquo; and &ldquo;unlocks a 110MM patient TAM who could benefit from a non-prescription CGM, including 96MM prediabetics,&rdquo; he added.
GLP-1 will be a &ldquo;companion therapy&rdquo; for Stelo and further drive CGM adoption, Singh wrote. &ldquo;We see room for higher estimate revisions and multiple expansion,&rdquo; he added.
DXCM Price Action: Shares of DexCom had risen by 0.75% to $134.04 at the time of publication on Tuesday.
&nbsp;

DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst Says

During the last three months, 4 analysts shared their evaluations of DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated DexCom and provided 12-month price targets. The average target is $153.25, accompanied by a high estimate of $165.00 and a low estimate of $147.00. This current average reflects an increase of 11.32% from the previous average price target of $137.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1710244862_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of DexCom among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$151.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$147.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DexCom's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Delving into DexCom's Background</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>A Deep Dive into DexCom's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 26.9% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.78%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): DexCom's ROE stands out, surpassing industry averages. With an impressive ROE of 11.82%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): DexCom's ROA stands out, surpassing industry averages. With an impressive ROA of 3.99%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.25, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For DexCom's Future

RBC Capital analyst Shagun Singh initiates coverage on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform rating and announces Price Target of $165.

RBC Capital Initiates Coverage On DexCom with Outperform Rating, Announces Price Target of $165

On CNBC&rsquo;s &quot;<a href="https://www.cnbc.com/video/2024/03/06/final-trades-sl-green-palantir-and-dexcom.html">Halftime Report Final Trades</a>,&quot; Jenny Harrington&nbsp;of Gilman Hill Asset Management named SL Green Realty Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slg#NYSE">SLG</a>), which has a <a href="https://www.benzinga.com/real-estate/reit/24/02/37158736/back-to-the-boardroom-how-return-to-work-is-revitalizing-americas-office-reits"> 6% dividend yield. </a>
On Jan. 24, SL Green Realty posted weaker-than-expected results for its fourth quarter, posting sales of $131.93 million, missing market estimates of $161.36 million.
Bryn Talkington of Requisite Capital Management said the commercial business of Palantir Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pltr#NYSE">PLTR</a>) is exploding to the upside and believes that there is a &quot;really long room to run.&quot;
On March 6, the Army Contracting Command &ndash; Aberdeen Proving Ground (ACC-APG) has awarded Palantir USG, Inc. a prime contract worth $178.4 million for developing and delivering the Tactical Intelligence Targeting Access Node (TITAN) ground station system. TITAN, enabled by Artificial intelligence (AI) and machine learning (ML), represents the Army&rsquo;s <a href="https://www.benzinga.com/markets/equities/24/03/37508807/why-palantir-technologies-shares-are-soaring-wednesday">next-gen deep-sensing capability.</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Joseph Terranova of Virtus Investment Partners said DexCom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxcm#NASDAQ">DXCM</a>) is breaking out.
On Tuesday, the FDA approved DexCom&rsquo;s Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37522301/fda-approval-for-dexcoms-stelo-opens-continuous-glucose-monitoring-to-masses-analys">who does not use insulin</a>.
Price Action:
<ul>
<li>SL Green Realty shares gained 2% to close at $50.55 on Wednesday.</li>
<li>Palantir Technologies shares rose 9.9% to close at $26.16 during Wednesday&rsquo;s session.</li>
<li>Shares of DexCom climbed 9.8% to close at $133.72 on Wednesday.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37502729/cramer-this-reit-is-a-little-too-dicey-as-for-marathon-digital-own-the-pure"> Cramer - This REIT Is &#39;A Little Too Dicey&#39;; As For Marathon Digital, &#39;Own The Pure&#39;</a>
Image: Shutterstock

Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC's 'Final Trades'

Tuesday, the FDA approved&nbsp;DexCom Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) Stelo Glucose Biosensor System as the first over-the-counter (OTC)&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37509833/fda-approves-dexcoms-stelo-as-first-glucose-monitoring-device-without-prescription" rel="noreferrer noopener">continuous glucose monitor (CGM)</a>.&nbsp;
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older who does not use insulin.
William Blair&nbsp;states that although initial pricing details for Stelo are undisclosed, it is anticipated to be competitive with&nbsp;Abbott Laboratories&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) current cash-pay price of approximately $80 per month.&nbsp;
DexCom, historically priced slightly higher than Abbott, is estimated at $90 per month, with potential cost reductions for patients through HSA benefits based on their tax bracket.
The analyst notes the FDA&#8217;s suggestion of requiring prior iCGM (integrated Continuous Glucose Monitoring) approval for OTC devices sets a high regulatory standard, favoring established players like DexCom and Abbott.&nbsp;
Meeting the criteria for iCGM accuracy is expensive and time-consuming, creating a significant hurdle for potential competitors.
The market for Stelo, catering to non-insulin-dependent diabetics (over 25 million patients), offers substantial opportunities beyond the core insulin therapy markets, William Blair highlights.&nbsp;
With potential applications for prediabetics and metabolic health, the expanding prevalence of obesity and a growing number of type 2 diabetics contribute to a rising demand for CGM technology.
The combined market potential for DexCom and Abbott is estimated to reach over 100 million individuals, including prediabetics and potential metabolic health users, as the companies embark on their next growth phase.
Abbott has considered introducing Lingo, a product potentially receiving OTC approval, focusing on health and wellness.&nbsp;
However, it&#8217;s worth highlighting that Stelo, at least in the short term, stands out as the sole OTC device designed specifically for type 2 non-insulin-dependent diabetics.
Price Action: DXCM shares closed higher by 7.83% at $131.32 on the last check Wednesday.
Photo via Company

Large Cap

Health Care

Movers

FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's

Markets rallied across the board on Wednesday, erasing the uptick in volatility seen in the previous session, following reassurances from Fed Chair Jerome Powell regarding the Fed&#8217;s willingness to ease monetary policy in 2024 if inflation consistently moves <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37514990/powell-stresses-need-for-more-data-before-considering-rate-cuts-downplays-recession-commer">toward the 2% target.</a>
On Wall Street, all indices saw gains in midday trading, with the tech-heavy Nasdaq 100 leading the way, up by 1.2%, outperforming both the S&amp;P 500, which rose by 0.8%, and the Dow Jones, which saw a 0.6% increase. Each of the eleven sectors comprising the S&amp;P 500 reported gains, indicating a widespread rally in the stock market.
Small-cap stocks also saw notable gains, with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) up by 1%, poised to recover losses from Tuesday.
Among the standout performers within the Magnificent Seven, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) once again led the pack, up by over 3%, fueled by a broader surge in the semiconductor industry.
Moreover, the bullish sentiment spilled over into other asset classes, with bonds, commodities, and cryptocurrencies all benefiting from the decline in the greenback and Treasury yields.
Gold, represented by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), surged by 0.8%, surpassing the $2,150/oz mark and marking new all-time highs. West Texas Intermediate (WTI) crude rose by 2.4% to $80 per barrel, reaching the highest level in four months, following EIA data revealing a lower-than-expected surge in weekly inventories.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reclaimed $67,000, bouncing back following a drop to $60,000 on Tuesday shortly after reaching record highs.
<h2 class="wp-block-heading">Wednesday&#8217;s Performance In US Major Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,103.90</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,073.72</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,121.78</td>
<td>0.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,776.17</td>
<td>0.5%</td>
</tr>
</tbody>
</table>
</figure>
The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.8% to $511.45, the&nbsp;SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) surged 0.5% to $388.19 and the tech-heavy&nbsp;Invesco QQQ Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.2% to $441.15, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.&nbsp;
The&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), was the top performer, up by 1.4%, while the&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) slightly lagged behind, up by 0.2%.&nbsp;
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h2>
<ul>
<li>CrowdStrike Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) rose over 13% after the company reported better-than-<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37514294/crowdstrike-shares-explode-on-q4-earnings-12-analysts-revise-their-forecasts#:~:text=Analyst%20Matthew%20Hedberg%20reiterated%20an,FCF%20margin%2C%E2%80%9D%20Hedberg%20said.">expected results last quarter. </a></li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rallied nearly 12% after winning a prime contract worth $178.4 million from the U.S. Army for developing and delivering the&nbsp;<a href="https://www.benzinga.com/pressreleases/24/03/b37505420/army-selects-palantir-to-deliver-titan-next-generation-deep-sensing-capability-in-prototype-matura" target="_blank" rel="noreferrer noopener">Tactical Intelligence Targeting Access Node (TITAN) ground station system</a> </li>
<li>New York Community Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) plummeted by 42% after news surfaced that the troubled regional bank is pursuing equity capital raising.</li>
<li>Despite surpassing earnings forecasts, Nordstrom Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) experienced a decline of over 15% as it disclosed weaker-than-anticipated guidance for 2024. In a similar fashion, Foot Locker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) fell 30%. </li>
<li>Other companies reacting to earnings are Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>), down about 1%, Campbell Soup Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>), down by 0.3%, United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>), down 15%, Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>), down 6%. </li>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) rose 9% after the FDA approved Stelo Glucose Biosensor System as the first over-the-counter (OTC)&nbsp;continuous glucose monitor (CGM).&nbsp;</li>
<li>Entravision Communications Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVC#NYSE">EVC</a>)&nbsp;tumbled by over 50% after the company received communication from&nbsp;Meta Platforms Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) that it intends to&nbsp;wind down its authorized sales partner (ASPs) program.</li>
<li>Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is due to report after the close.</li>
</ul>
Now Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37514990/powell-stresses-need-for-more-data-before-considering-rate-cuts-downplays-recession-commer">Powell Stresses Need For &#8216;More Data&#8217; Before Considering Rate Cuts, Downplays Recession, Commercial Real Estate Risks</a>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Earnings Beats

Earnings Misses

Equities

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Commodities

Small Cap

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

CRWD

SPDR Dow Jones Industrial Average ETF Trust

NVDA

NYCB

ROST

UNFI

VSCO

Select Sector SPDR-Consumer Discretionary

Stocks Surge, Gold Hits New All-Time High, Bitcoin Reclaims $67,000 As Powell Reassures Wall Street: What's Driving Markets Wednesday?

CNBC Halftime Report Final Trades: SL Green Realty, Palantir Technologies And DexCom

Tuesday, the FDA approved&nbsp;DexCom Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) Stelo Glucose Biosensor System as the first over-the-counter (OTC)&nbsp;<a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor" rel="noreferrer noopener">continuous glucose monitor (CGM)</a>.&nbsp;
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for anyone 18 years and older who does not use insulin.
The company said Stelo will be available online without a prescription&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/b37494632/stelo-by-dexcom-first-glucose-biosensor-to-be-cleared-by-fda-as-over-the-counter" rel="noreferrer noopener">starting summer of 2024</a>.
This system is not for individuals with problematic hypoglycemia (low blood sugar) as the system is not designed to alert the user to this potentially dangerous condition.&nbsp;
The Stelo Glucose Biosensor System uses a wearable sensor paired with an application installed on a user&#8217;s smartphone or other smart device to continuously measure, record, analyze, and display glucose values.&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37034413/continuous-glucose-monitor-maker-dexcoms-q4-profit-triples-on-volume-growth-and-new" rel="noreferrer noopener">Continuous Glucose Monitor Maker Dexcom&#8217;s Q4 Profit Triples On Volume Growth And New Customer Additions</a>.
Users can wear each sensor for up to 15 days before replacing it with a new sensor. The device presents blood glucose measurements and trends every 15 minutes in the accompanying app.&nbsp;
Data from a clinical study provided to the FDA showed that the device performed similarly to other iCGMs.&nbsp;
Adverse events reported in the study included local infection, skin irritation, and pain or discomfort.
The company says there are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring technology.&nbsp;
Dexcom G7 is available with a prescription. Stelo cleared for use without a prescription, will make it even easier for this population to access leading CGM technology and will provide an option for those who do not have insurance coverage for CGM.

Price Action: DXCM shares are trading higher by 2.64% at $125.50 premarket on the last check Wednesday.
Photo via Company

FDA Approves Dexcom's Stelo As First Glucose Monitoring Device Without Prescription

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The latest employment figures saw indices rise. However, losses earlier in the week persist as investors remain <a href="https://finance.yahoo.com/news/us-stocks-wall-street-indexes-202801487.html">cautious of the Fed&rsquo;s stance</a> on interest rate adjustments. Amid this climate, it&rsquo;s essential to highlight a few potential Nasdaq stocks to sell. They could represent a shift from the buoyant sentiment a month ago when the Nasdaq and broader markets reached successive record highs. While returns have been strong year-to-date (YTD), some analysts argue that exuberance may be fading as the Nasdaq posted near double-digit gains in Q1. Expecting higher valuations to face corrections and better align with company fundamentals is reasonable. For context, the Nasdaq&rsquo;s price-to-earnings multiple of 33.4 is at its <a href="https://www.bloomberg.com/quote/NDX:IND">highest since the dot-com</a> bubble. This doesn&rsquo;t imply there will be a definite turn, but it raises the prospects for certain Nasdaq stocks to sell as they have become overvalued.



Should the Fed refrain from or delay expected rate cuts in June, higher borrowing costs could impact firms with high debt. Such companies could become the prime Nasdaq stocks to sell before potential price reversals. Even without a <a href="https://money.usnews.com/investing/articles/will-the-stock-market-crash-risk-factors">major market downturn</a>, price declines could still occur, with investors on the lookout for Nasdaq stocks to sell. The three Nasdaq-listed companies that appear ripe for reassessment before reality sets in are:&#8203;



<h2>DoorDash (DASH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/04/doordash1600-300x169.jpg" alt="Close up of Doordash (DASH) logo and symbol displayed at the entrance to one of their offices"><div>Source: Sundry Photography / Shutterstock.com</div></div>DoorDash (NASDAQ:<a href="https://investorplace.com/stock-quotes/dash-stock-quote/">DASH</a>) is one of the Nasdaq stocks to sell as the delivery business faces intense competition. Despite surging demand during the pandemic and <a href="https://www.baselinemag.com/news/soaring-food-delivery-costs-trigger-customer-discontent/">soaring delivery costs</a>, the company has consistently failed to achieve profitability. DoorDash symbolizes this trend, as its revenues steadily increase year-over-year (YOY) while profits remain red.



Investors betting on such companies are looking to achieve profitability in the future. However, with high inflation, increasing interest rates, and DoorDash&rsquo;s <a href="https://au.lifestyle.yahoo.com/doordash-layoffs-153656792.html">ongoing struggles</a> to get margins under control, it&rsquo;s worth considering as one of the Nasdaq stocks to sell. The company will report <a href="https://finance.yahoo.com/news/doordash-announce-first-quarter-2024-130000107.html">earnings in early May</a>. Failing to assure hopes of near-term profitability could negatively impact its stock price. This could mark it as a main Nasdaq stock to sell.



<h2>DexCom (DXCM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/dxcm-stock-1-300x169.jpg" alt="Dexcom (DXCM) logo on an app store page on a mobile phone"><div>Source: FOOTAGE VECTOR PHOTO / Shutterstock.com</div></div>DexCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>) is yet another one of the potential Nasdaq stocks to sell. DexCom, which provides glucose meters, saw its stock tank when weight-loss drugs were released last year. This was expected to lower the demand for obesity-related monitoring devices. However, since last October&rsquo;s market upturn, share prices have rebounded. They have surpassed last year&rsquo;s levels despite DXCM <a href="https://investors.dexcom.com/news/news-details/2024/Dexcom-Reports-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results/default.aspx">providing no major changes</a> to its outlook. Regardless of this resurgence, savvy investors looking for Nasdaq stocks to sell may want to focus on DexCom.



DXCM has surged 82% since last October, but the company anticipates only 16-21% organic revenue growth. Its <a href="https://finance.yahoo.com/quote/DXCM?.tsrc=fin-srch">P/E ratio has soared to 106x</a>, which puts it at risk of returning to a valuation more in line with the healthcare <a href="https://simplywall.st/markets/us/healthcare/healthcare-services">sector average of 23x</a>.&#8203; For investors tracking Nasdaq stocks to sell, DexCom&rsquo;s valuation could be an opportunity to reassess their positions before the stock realigns with the broader sector&rsquo;s norms.



<h2>Advanced Micro Devices (AMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/12/amd1600-1-300x169.png" alt="Advanced Micro Devices, Inc. (AMD) logo in the building at CNE in Toronto. AMD is an American semiconductor company."><div>Source: JHVEPhoto / Shutterstock.com</div></div>Advanced Micro Devices (NASDAQ:<a href="https://investorplace.com/stock-quotes/amd-stock-quote/">AMD</a>) is the final pick of the Nasdaq stocks to sell. The company has benefited from the growth in artificial intelligence. However, its <a href="https://finance.yahoo.com/news/advanced-micro-devices-inc-nasdaq-120023688.html">performance has outpaced its results</a> as its sales and earnings have not matched the stock price momentum. AMD was slow to offer its own AI chips, which explains its <a href="https://finance.yahoo.com/quote/AMD/financials">revenue decline</a>. So, unless the company transforms its execution in the following quarterly report, investors may lose patience given its <a href="https://finance.yahoo.com/quote/AMD?.tsrc=fin-srch">high P/E of 310x</a>.



Given this inflated valuation, AMD&rsquo;s stock could be one of the Nasdaq stocks to sell, as it is exposed to higher risks. Investors closely monitoring Nasdaq stocks to sell might consider AMD&rsquo;s high valuation as a warning flag. This suggests the possibility of a realignment to a price level matching its performance.



On the date of publication, Stavros Tousios did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Stavros Tousios, MBA, is the founder and chief analyst at Markets Untold. With expertise in FX, macros, equity analysis, and investment advisory, Stavros delivers investors strategic guidance and valuable insights.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/nasdaq-nightmares-3-stocks-to-sell-before-reality-sets-in/">Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The burgeoning interest in obesity drugs, particularly GLP-1 products such as Ozempic, Saxenda, and Mounjaro, marks a significant shift in the global approach to managing obesity. In this article, we look at three obesity drug stocks investors should consider.



Shares of the companies producing these drugs soared in 2023 as demand outstripped supply and projections suggesting a market growth to $150 billion annually within the next decade. The surge is driven by the drugs&rsquo; effectiveness not only in weight loss but also in potentially improving overall health, such as reducing heart failure symptoms.&nbsp;



The accessibility of these treatments is hindered by insurance hurdles, notably Medicare&rsquo;s exclusion of weight loss medication coverage due to a 2003 law, raising concerns about equitable access to potentially life-saving treatments.



The escalating demand has led to shortages, fueling fears about patients turning to the black market for alternatives, which could have dangerous consequences. As the world grapples with these issues, the long-term health impacts and the economic implications of the obesity drug boom remain critical areas for ongoing scrutiny and policy adaptation.



Nearly a quarter of the world&rsquo;s population <a href="https://www.morganstanley.com/im/en-us/individual-investor/insights/articles/glp1-the-weight-of-speculation.html" target="_blank">will be obese by 2035</a>, a significant increase from 14% in 2020, according to latest projections. In the United States alone, the economic fallout from obesity is staggering, with the negative impact on the gross domestic product (GDP) estimated at 3.6%. According to Morgan Stanley (NYSE:<a href="https://investorplace.com/stock-quotes/ms-stock-quote/">MS</a>), this figure translates into a potential $1.24 trillion in indirect costs, primarily due to lost productivity.



Let&rsquo;s take a look at the top three obesity drug stocks set to skyrocket.



<h2>Eli Lilly (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/eli-lilly-lly-stock-sign-1600-300x169.jpg" alt="Eli Lilly (LLY) sign on corporate building with blue sky in background"><div>Source: shutterstock.com/Michael Vi</div></div>Eli Lilly (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) is a global pharmaceutical leader which has made significant strides in the obesity treatment market with its innovative product, Mounjaro (tirzepatide). Mounjaro, initially approved for managing type 2 diabetes, has shown promising results in weight loss, positioning it as a potential game-changer in obesity management.



Eli Lilly&rsquo;s diabetes medication, Mounjaro, achieved an impressive <a href="https://finance.yahoo.com/news/lilly-sales-surge-obesity-diabetes-121600624.html" target="_blank">$5 billion in sales during 2023,</a> its debut year, indicating a high demand for this therapy and similar drugs. The strong performance contributed to Lilly&rsquo;s annual revenue reaching $34 billion, marking a 20% growth from the previous year.



In the fourth quarter alone, <a href="https://tokenist.com/lly-vs-nvo-which-one-is-likely-to-become-a-1t-company-first/" target="_blank">revenue hit $9.35 billion</a>, surpassing expectations by 5%. Mounjaro now represents 27% of all U.S. prescriptions for injectable incretins, a class of drugs that enhance insulin production through hormone modulation.&nbsp;



Meanwhile, sales for Trulicity, Lilly&rsquo;s older incretin-based drug, declined by 4% to $7 billion, though it remains a key product. Additionally, Lilly&rsquo;s obesity drug Zepbound, sharing Mounjaro&rsquo;s active ingredient, launched in the fourth quarter, generating $176 million in sales by year-end. According to Morgan Stanley&rsquo;s projection, Zepbound could generate between $2.2 billion and $2.7 in sales.



<h2>Novo Nordisk (NVO)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/novo-nordisk.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/novo-nordisk-300x169.png" alt=""></a>Novo Nordisk A/S (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) is also at the forefront of the obesity treatment market with its revolutionary drugs, Saxenda and Wegovy. These revolutionary products, which suppress appetite and promote weight loss, pushed NVO stock to record highs and positioned it as one of the top obesity drug stocks to buy.



In January, the Danish pharmaceutical giant announced a surge in sales for its renowned obesity and diabetes medications, Wegovy and Ozempic, propelling its valuation beyond the $500 billion mark.&nbsp;



The stock price surge has established Novo Nordisk as Europe&rsquo;s highest-valued firm, surpassing even luxury behemoth LVMH. The obesity drug sector saw a staggering 154% increase in sales, primarily driven by Wegovy, while diabetes medication sales, including Ozempic, rose by 52%.&nbsp;



Sales in the Diabetes and Obesity care sector <a href="https://www.theguardian.com/business/2024/jan/31/obesity-drug-ozempic-novo-nordisk-record-wegovy" target="_blank">rose by 38%</a> to DKK 215.1 billion, with a remarkable 42% growth at constant exchange rates. This significant increase was primarily propelled by a 48% growth in GLP-1 diabetes treatment sales, which reached 52% in constant rates. Furthermore, the Obesity care segment was up by 147% in Danish Kroner to 41.6 billion, and achieved an even more impressive 154% growth at constant exchange rates.



<h2>DexCom (DXCM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/dxcm-stock-1-300x169.jpg" alt="Dexcom (DXCM) logo on an app store page on a mobile phone"><div>Source: FOOTAGE VECTOR PHOTO / Shutterstock.com</div></div>DexCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>) is one of the major players in glucose monitoring technology, primarily focusing on diabetes management rather than obesity products. The company&rsquo;s Continuous Glucose Monitoring (CGM) systems provide real-time glucose readings, aiding people with diabetes in managing their condition and potentially contributing to obesity management by enabling better glycemic control.



Back in February, Dexcom <a href="https://investors.dexcom.com/news/news-details/2024/Dexcom-Reports-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results/" target="_blank">reported</a> a 27% increase in revenue to $1.03 billion in the fourth quarter of 2023 compared to the previous year, with both U.S. and international markets contributing equally to this growth. The company&rsquo;s operating income rose to $216.9 million for the same period of the year.&nbsp;



On the strategic front, Dexcom submitted Stelo, a new sensor for type 2 diabetes patients not on insulin, for FDA review and enhanced its pump connectivity options. This includes the integration with Tandem Diabetes Care&rsquo;s t:slim X2 insulin pump and Beta Bionics&rsquo; iLet Bionic Pancreas. Moreover, Dexcom is innovating with a direct-to-watch feature pending FDA approval, allowing users to receive glucose readings directly on a smartwatch.



On the date of publication, Shane Neagle did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://protect-us.mimecast.com/s/XtC3C1wq33iErOvYSGOsXg?domain=investorplace.com/">Publishing Guidelines</a>.
<div>Shane Neagle is fascinated by the ways in which technology is poised to disrupt investing. He specializes in fundamental analysis and growth investing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/3-obesity-drug-stocks-set-to-skyrocket-as-demand-goes-wild/">3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Currently, the tech landscape is undergoing a seismic shift, driven by a new breed of game-changing stocks. These disruptive innovators are leveraging cutting-edge technologies to transform how we live, work and play, fundamentally reshaping entire industries.



From emerging startups to established giants, the tech landscape is ablaze with disruptive forces. Metrics suggest that the digital transformation <a href="https://www.fortunebusinessinsights.com/digital-transformation-market-104878">market could explode</a> from $2.71 trillion in 2024 to a staggering $12.35 trillion by 2032. Thus, identifying the pioneers driving this change is crucial for investors seeking substantial growth. However, discerning true disruptive potential from mere hype remains a critical challenge.



Let&rsquo;s identify three game-changing stocks. Each are strategically positioned to capitalize on this transformative wave and generate long-term value for investors.



<h2>GitLab (GTLB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/gtlb1600-300x169.png" alt="In this photo illustration the GitLab (GTLB) logo seen displayed on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>Topping our list of game-changing stocks is GitLab (NASDAQ:<a href="https://investorplace.com/stock-quotes/gtlb-stock-quote/">GTLB</a>). This software developer offers a comprehensive DevSecOps platform, streamlining the entire software development lifecycle to <a href="https://investorplace.com/2024/03/3-underappreciated-tech-stocks-that-deserve-some-investor-love/">deploy software efficiently</a>.



Management of the software development company has recently reported impressive fourth quarter and full year 2024 financial results. Quarterly revenue surged 33% year-over-year (YOY) to $163.8 million. Net income showed significant improvement, reaching $13.2 million, compared to a loss of $13.8 million in the prior-year quarter.



Further solidifying its commitment to software security, GitLab <a href="https://ir.gitlab.com/news-releases/news-release-details/gitlab-acquires-oxeye-advance-application-security-governance">announced the acquisition</a> of Oxeye on March 20, 2024.&nbsp;Oxeye, which provides cloud-native application security and risk management solutions, will likely accelerate GitLab&rsquo;s Static Application Security Testing (SAST) roadmap. In addition, Oxeye&rsquo;s capabilities could augment GitLab&rsquo;s software composition analysis and compliance tools.



Despite its strong fundamentals, GTLB stock has underperformed the broader market, declining almost 6% year-to-date (YTD). We should highlight that shares are trading at a premium valuation of about 15 times sales. Yet, Wall Street remains bullish, with a <a href="https://edition.cnn.com/markets/stocks/GTLB">median 12-month price target</a> of $75.00, implying a potential upside of 30% from current levels.



<h2>Synopsys (SNPS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/snps1600-300x169.png" alt="Person holding mobile phone with logo of American technology company Synopsys Inc. (SNPS) on screen in front of web page. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>Synopsys (NASDAQ:<a href="https://investorplace.com/stock-quotes/snps-stock-quote/">SNPS</a>) emerges as another disruptive force on our list.&nbsp; A pioneer in Electronic Design Automation (EDA), Synopsys shapes the future of &ldquo;Smart Everything&rdquo; with cutting-edge software products and consulting services. From self-driving cars to secure communication networks, Synopsys is making its mark.



The tech company has recently <a href="https://investor.synopsys.com/news/news-details/2024/Synopsys-Posts-Financial-Results-for-First-Quarter-Fiscal-Year-2024/">delivered solid results</a> for its first quarter of fiscal year 2024, exceeding analyst expectations. Quarterly revenue surged 21% YOY to $1.65 billion, while adjusted earnings per diluted share of $3.56 came in above guidance. Investors&rsquo; have been pleased with Synopsys&rsquo; strong market position, sending the SNPS stock up 10% YTD, 



Earlier in 2024, Synopsys <a href="https://investor.synopsys.com/news/news-details/2024/Synopsys-to-Acquire-Ansys-Creating-a-Leader-in-Silicon-to-Systems-Design-Solutions/default.aspx">announced a definitive agreement</a> to acquire Ansys (NASDAQ:<a href="https://investorplace.com/stock-quotes/anss-stock-quote/">ANSS</a>). This merger is expected to create a leading force in silicon-to-systems design solutions, bringing together Synopsys&rsquo; EDA tools with Ansys&rsquo; broad simulation and analysis portfolio.



Analysts have a <a href="https://edition.cnn.com/markets/stocks/SNPS">12-month price target</a> of $639 for SNPS, suggesting an additional 14% upside from current levels. But the company is richly valued with a forward price-to-earnings (P/E) ratio of 43.1 and price-to-sales (P/S) ratio is of 14. 



<h2>ALPS Disruptive Technologies ETF (DTEC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/01/shutterstock_1917075950-300x169.png" alt="ETF Investment index funds concept with letter wooden blocks and lots of different currencies, ETFs to buy. Emerging markets ETFs"><div>Source: Eviart / Shutterstock.com</div></div>Rounding out our list of <a href="https://www.alpsfunds.com/exchange-traded-funds/dtec">disruptive forces</a> is the ALPS Disruptive Technologies ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/dtec-stock-quote/">DTEC</a>). Launched in December 2017, this thematic fund grants investors exposure to companies using disruptive technologies.



DTEC has diversified portfolio of 95 stocks, while the top 10 holdings constitute 12% of $99.3 million in total assets. Leading names include Hong Kong-based Xinyi Solar Holdings (OTCMKTS:<a href="https://investorplace.com/stock-quotes/xishy-stock-quote/">XISHY</a>), Align Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/algn-stock-quote/">ALGN</a>), Dexcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>), First Solar (NASDAQ:<a href="https://investorplace.com/stock-quotes/fslr-stock-quote/">FSLR</a>) and PayPal (NASDAQ:<a href="https://investorplace.com/stock-quotes/pypl-stock-quote/">PYPL</a>).



The sector breakdown of DTEC includes clean energy &amp; smart grid (10.58%), healthcare innovation (10.31%) and cybersecurity (10.17%). Geographically, the fund leans toward U.S. companies (65.91%), while maintaining exposure to China (5.38%) and Japan (4.72%). Such a diversification enhances DTEC&rsquo;s ability to capture growth opportunities across various sectors and regions.



So far in 2024, the fund&rsquo;s performance has been flat. Its trailing P/E ratio of 35.6 reflects the growth potential of the holdings.&nbsp;Finally, interested investors should note the expense ratio of 0.5%.



On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Tezcan Gecgil, PhD, began contributing to InvestorPlace in 2018. She brings over 20 years of experience in the U.S. and U.K. and has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Publicly, she has contributed to <a href="https://www.investing.com/">investing.com</a> and the U.K. website of <a href="https://www.fool.com/">The Motley Fool.</a></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/disruptive-forces-3-game-changing-stocks-reshaping-the-tech-landscape/">Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape

Portfolio Review: The Cat, The Tortoise And Me

In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom (DXCM – Research Report), with a price tar...

RBC Capital Keeps Their Buy Rating on Dexcom (DXCM)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
People are interested in ETFs for weight loss because of Oprah&rsquo;s TV show &ldquo;Shame, Blame, and the Weight Loss Revolution,&rdquo; which was about weight loss drugs. A lot of people are upset that she&rsquo;s talking to patients and doctors about using prescription drugs to lose weight, but it&rsquo;s still causing a stir.



It&rsquo;s also big news that <a href="https://www.usatoday.com/story/entertainment/tv/2024/03/15/oprah-winfrey-weight-watchers-exit-medication-abc-special/72987200007/#:~:text=Oprah%20Winfrey%20opens%20up%20about%20exiting%20Weight%20Watchers%20after%20using%20weight%20loss%20drug&amp;text=Oprah%20Winfrey%20is%20opening%20up,weight%20loss%20medication%20in%202023.">Oprah is leaving the Weight Watchers board</a>. The fact that she backs drugs like Mounjaro, Wegovy and Ozempic shows how times are changing for everyone. It&rsquo;s always been hard for the famous talk show host to lose weight. But because she was so famous, everything she suggested to lose weight sold out very quickly.



In other words, we see the same pattern with drugs that help people lose weight. Because of <a href="https://time.com/6958224/oprah-weight-loss-special-ozempic/">Oprah&rsquo;s ABC special</a>, the dieting business and the practice of dieting are changing. This is like what happened when she really tried to lose weight in 1998. The only difference is the methodology she&rsquo;s adopting.



But be careful while Oprah fights the social shame that comes with losing weight with Ozempic. Not only does Ozempic have side effects, but a lot of new medicines need testing.



Then, what is the safest thing to do with this trend? Investing in the best exchange-traded funds (ETFs) for weight loss can open up a lot of health and fitness-related doors for you. While Oprah plugs diet pills, let&rsquo;s look at three exchange-traded funds that can help you lose weight.



<h2>iShares US Healthcare Providers ETF (IHF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600d-300x169.jpg" alt="Healthcare professional in green scrubs standing with arms crossed."><div>Source: Shutterstock</div></div>The iShares US Healthcare Providers ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/ihf-stock-quote/">IHF</a>), up 11% in the past year, boasts a competitive expense ratio of 0.40% and a dividend yield of 0.78%. It is riding the Oprah momentum, which is turning back the clock to the late 90s. <a href="https://investorplace.com/cryptocurrency//"></a>



The expense ratio indicates the amount you will pay to own a fund over the course of a year. In this case, it is pretty reasonable, meaning there are no complaints to management. The yield might seem a bit ordinary, but this is an ETF we are talking about.



At the end of last year, IHF divided its shares five-to-one to reduce their value and increase the number of outstanding shares, which improved accessibility. 



One of the oldest weight-loss ETFs available, IHF focuses on the healthcare and nursing home industries and tracks the Dow Jones U.S. Select Health Care Providers Index.



Its reduced volatility in correlation with the market overall as a whole gives it the attributes of medium risk, which exhibits a beta of 0.72 and standard deviation of 17.20% over a 3-year historical time period.



IHF&rsquo;s <a href="https://www.ishares.com/us/products/239510/ishares-us-healthcare-providers-etf">portfolio&rsquo;s top holdings</a>, UnitedHealth Group (NYSE:<a href="https://investorplace.com/stock-quotes/unh-stock-quote/">UNH</a>), CVS Health (NYSE:<a href="https://investorplace.com/stock-quotes/cvs-stock-quote/">CVS</a>), Cigna (NYSE:<a href="https://investorplace.com/stock-quotes/ci-stock-quote/">CI</a>) and Humana (NYSE:<a href="https://investorplace.com/stock-quotes/hum-stock-quote/">HUM</a>), at 22%, 4%, 10% and 4%, respectively, offer many wellness programs that can ride the current Oprah momentum to the bank. These programs include diet plans from Humana, over-the-counter weight loss supplements at CVS MinuteClinics, nutritional counseling from Cigna and weight management plans through UnitedHealth&rsquo;s Optum.



<h2>The Obesity ETF (SLIM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/healthcare-stocks1600-300x169.png" alt="drugs pill and stock chart growing up with money, business and economic news background. business profit analysis trend and future. hospital and healthcare segment. Healthcare stocks"><div>Source: WHYFRAME / Shutterstock.com</div></div>Janus Henderson&rsquo;s The Obesity ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/slim-stock-quote/">SLIM</a>) tracks the performance of global companies offering obesity-related services, but the twist is that several fields fall under this category. Just as we saw with IHF, there is no singular way to invest in healthcare, biotechnology, pharmaceuticals, plus-size clothing, weight loss programs and medical devices.



The Obesity ETF invests at least 80% of its net assets in the stocks that comprise the&nbsp;Solactive Obesity Index. Its lack of diversity compared to other exchange-traded funds means it may favor investing in specific companies or industries.



At $11.63 million in net worth, SLIM offers a dividend yield of 0.57%. The fund&rsquo;s disastrous losses as of late &mdash; a year-to-date total loss of 11.27% &mdash; are due to the unpredictable nature of the healthcare industry.



Companies involved in treating diabetes and obesity account for about three quarters of SLIM&rsquo;s assets. Regarding ownership, Novo Nordisk&lsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) 20% and DexCom&lsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>) 13% are at the top.



As a weight loss product manufacturer, SLIM owns Novo Nordisk and Herbalife (NYSE:<a href="https://investorplace.com/stock-quotes/hlf-stock-quote/">HLF</a>). Obese adults can take one of two weight management medications made by industry giant Novo Nordisk: Wegovy or Saxenda. Among Herbalife&rsquo;s many health and weight loss aids are protein shakes, bars and teas. It&rsquo;s worth remembering that Wegovy is a name that has been popping up a lot ever since Oprah decided to create a major cultural boost for these prescription drugs.



Several prominent <a href="https://finance.yahoo.com/quote/SLIM/holdings/">companies are part of its portfolio</a>, including Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>), Insulet Corporation (NASDAQ:<a href="https://investorplace.com/stock-quotes/podd-stock-quote/">PODD</a>), and DexCom. Weight loss aids made by these companies, which boost metabolic health, make managing diabetes easier. Healthcare providers and medical device manufacturers all have an indirect interest in helping with weight management.



<h2>VanEck Pharmaceutical ETF (PPH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>VanEck Pharmaceutical ETF&lsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/pph-stock-quote/">PPH</a>) focus on pharmaceuticals makes for an interesting analysis. It&rsquo;s the main beneficiary of the Oprah-led boom.



The ETF has increased by more than 7% to $85.44 in the last year. Shares are issued and redeemed on demand by this open-ended investment company. On Mar. 31, net assets and share class size totaled $543.2 million.



With a net expense ratio of only 0.36%, this shows the fund&rsquo;s operational expenditures are managed effectively. 



VanEck Pharmaceutical ETF&rsquo;s portfolio helped develop weight-loss and treatment drugs. Tigepatide, sold as Mounjaro, has made Eli Lilly (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) a weight loss pharmaceutical giant. Tirzepatide, first approved for type 2 diabetes, regulates hunger and insulin secretion by blocking GLP-1 and GIP receptors. This medication can reduce weight by 20% in overweight or obese non-diabetics.



Novo Nordisk has benefited from semaglutide, which is sold as Wegovy for obesity and Ozempic for diabetes, two names linked to Oprah and her new attitude toward weight management. This chronic weight management program helps patients lose 15%, making Wegovy famous. 



On the date of publication, Faizan Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Faizan Farooque is a contributing author for InvestorPlace.com and numerous other financial sites. Faizan has several years of experience in analyzing the stock market and was a former data journalist at S&amp;P Global Market Intelligence. His passion is to help the average investor make more informed decisions regarding their portfolio.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom/">3 Weight-Loss ETFs to Profit From the Obesity Drug Boom</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Weight-Loss ETFs to Profit From the Obesity Drug Boom

Today's episode of Full Court Finance at Zacks dives into the recent stock market pullback. We then turn our attention to three innovators in their respective industries—Vertiv, Align Technology, and DexCom, Inc.

3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback

Top high growth investment ratio stocks from each sector - GS

DexCom Q1 2024 Earnings Preview

AAOI

ADSK

ALGN

AMZN

APPS

APTV

ASPN

AXON

BIIB

CDNS

CRSP

DASH

DLTR

DTEC

FANG

FFIV

FSLR

GOOGL

GRMN

GTLB

ILMN

INCY

INTC

JNPR

KEYS

MELI

MPWR

MTCH

NFLX

NTAP

ORCL

OTGLF

OTGLY

PODD

PYPL

QCOM

SGOV

SNPS

TLRY

TNDM

TRMB

UBER

XISHY

YETI

ZBRA

Press Releases

Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump

Synchron Appoints Andy Rasdal to Board of Directors

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Dexcom Announces Upcoming Conference Presentation

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time